EasyMed Services Inc. (CNSX:EZM)(OTCBB:EMYSF)(MUN:EY6) ("ESI") would

like to add further pertinent background details of its intended

partner Biosign Technologies Inc. (TSX VENTURE:BIO) ("Biosign") for

our investors. Due to some diffusion issues, a background to Biosign

in our announcement dated April 2nd was not relayed.

We were pleased to announce on April 2nd that ESI have entered into a

letter of intent dated April 1, 2012 (the "Letter of Intent") with

Biosign Technologies Inc. (TSX VENTURE:BIO) ("Biosign") to complete a

business combination (the "Transaction"). BIO, a public company with

headquarters in Toronto, Canada, provides biomedical systems. Key

applications include intelligent systems for non-invasive monitoring

of common health risks associated with blood pressure, glucose, and

medication. The core technology combines measurement, analysis, and

rapid knowledge formation to support health monitoring across global

markets. Upon completion of the Transaction, it is intended that the

combined entity will continue to carry on the business of ESI and will

be listed on the TSX-V.

For full information on the proposed transaction between ESI and

Biosign please refer to the press release dated on April 2nd 2012.

We outline for our investors a description of Biosign to allow them to

fully understand Biosign's extremely compatible resources with ESI

going forward.

Information Concerning Biosign. Biosign Technologies Inc. is a public

company traded on the TSX - Venture Exchange ("TSX-V") under the

symbol BIO and was formed via an amalgamation under the Business

Corporations Act (Ontario) on July 14, 2006. The predecessor operating

company was Biosign Technologies Inc. which was incorporated under the

Business Corporations Act (Ontario) on March 11, 2004.

Biosign is an ISO 13485 Certified Medical Device company that has

invested in excess of $15million to develop technologies, products and

initiatives to address critical problems in global health care.

Biosign is committed to becoming the "world's health monitor" with a

robust, integrated and portable system that provides valuable

information to stakeholders. Biosign's breakthrough technology and

continued innovation serve the Company's mission to make health care

safe, simple, and sensible.

Biosign provides an end-to-end solution for non-invasive monitoring,

analysis and reporting of health data critical to the management of

cardiovascular conditions through their proprietary platform "UFIT".

The UFIT@ cuff painlessly captures the pulse waveform from the

patient's pulse and transmits it to the cloud through a computer.

Biosign proprietary algorithms analyze the data in seconds to report

blood pressure and other cardiovascular measurements. Biosign's

analysis and reporting tools give patients and their healthcare team

secure access to real-time and longitudinal health information for

treatment planning, evaluation, and management.

In October 2010 Biosign acquired Healthanywhere ("HA") for

consideration of approximately $3,400,000. The HA intellectual

property includes a 510k clearance from the U.S. Food and Drug

Administration for the HA solution as a Class II medical device. HA

provides software solutions addressing the continuum of care from

wellness promotion and self-managed care to chronic disease


ESI Chief Executive Officer Andrew Ritchie commented: "We want to

inform our shareholders and the broader investment community of the

great rationale for the proposed merger between these two companies.

After having executed the Joint-Venture agreement with Biosign earlier

this year it became evident that a merger was the right way forward to

maximize both companies' unique technical and human resources in the

domain of telemedicine."

About EasyMed Services Inc.

EasyMed Services, Inc. (CNSX:EZM)(OTCBB:EMYSF)(MUN:EY6) is a global

medical information technology company delivering an end to end

patient care solution through mobile phone/PDA and server technologies

offering specialized services and applications for healthcare,

insurance and pharmaceutical industries. We are committed to

world-class customer service and the protection of our clients'


For more information, visit

This news release contains forward-looking statements, which relate to

future events or future performance and reflect management's current

expectations and assumptions. These forward-looking statements reflect

management's current beliefs and are based on assumptions made by and

information currently available to the Company. Investors are

cautioned that these forward looking statements are neither promises

nor guarantees, and are subject to risks and uncertainties that may

cause future results to differ materially from those expected. These

forward-looking statements are made as of the date hereof and, except

as required under applicable securities legislation, the Company does

not assume any obligation to update or revise them to reflect new

events or circumstances.

The CNSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this release.